Bellissimo plans to study it in people living with diabetes and obesity, with a key focus on mechanism: allulose appears to stimulate GLP-1, a gut hormone that regulates blood sugar, appetite and digestion the same pathway targeted by drugs like Ozempic
These work together to stimulate the liver into optimizing the process of metabolism, elevate the movement of and utilization of fat, and boost the metabolic power of the body
Tirzepatide: The FDA removed tirzepatide from the national shortage list
Expected changes: Significant appetite reduction, often described as forgetting to eat Accelerated weight loss compared to semaglutide baseline Potential for constipation as gastric emptying slows further Increased satiety lasting longer between meals Weeks 13 through 16: tirzepatide 10 mg At 10 mg, you are firmly in the therapeutic range that surpasses maximum semaglutide dosing
Common research applications include: Obesity and Weight Loss Modeling: Studying the mechanisms of NNMT inhibition on fat oxidation and energy expenditure
These trials collectively indicate that whilst GLP-1 receptor agonists appear safe in Parkinson's populations, the magnitude of clinical benefit remains uncertain